Physician profile
Mahmoud Al Masry
NPI 1851694889
$4,139.11
in general payments reported to CMS, 2019-2025
17 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.88 · 2020: $65.23 · 2021: $56.26 · 2022: $814 · 2023: $1,435 · 2024: $260 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694 · Travel and Lodging: $963 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.87 |
| Travel and Lodging | $963.37 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,298.52 | 2022-2025 | Proclaim, Eterna, Octrode |
| Spr Therapeutics, INC | $790.20 | 2022-2025 | Sprint Pns System |
| Medtronic, INC. | $706.25 | 2022-2025 | Intellis Adaptivestim |
| Hydrocision, INC. | $500.00 | 2023 | Tenjet |
| Abbvie INC. | $238.79 | 2022-2023 | Qulipta |
| Nevro Corp. | $124.71 | 2023 | Senza |
| Biohaven Pharmaceutical Holding Company Ltd. | $82.75 | 2022 | |
| Curonix LLC | $82.72 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $74.17 | 2020-2021 | |
| Lundbeck LLC | $47.70 | 2022-2023 | Vyepti |
| Ucb, INC. | $47.32 | 2020 | |
| Pfizer INC. | $46.60 | 2023 | |
| Janssen Pharmaceuticals, INC | $30.21 | 2019 | |
| Bioventus LLC | $18.39 | 2023 | Stimrouter Implantable Kit |
| Si-Bone, INC. | $17.75 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $16.67 | 2019 | |
| Relievant Medsystems, INC. | $16.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Al Masry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.